GC Biopharma's Hunter Syndrome Treatment Gains Approval in India and Taiwan: A Significant Milestone for Rare Disease Management
GC Biopharma, a prominent global player in the pharmaceutical landscape from South Korea, has recently made headlines by securing marketing approvals for its innovative treatment, Hunterase IV, aimed at addressing Hunter syndrome in both India and Taiwan. This development signals a crucial step towards expanding access to treatment for this challenging condition in Asia, following approvals in other critical markets such as Japan and China.
On August 24, 2026, GC Biopharma announced that its Hunter syndrome therapy, Hunterase IV, has received the go-ahead from India’s Central Drugs Standard Control Organisation (CDSCO) as well as Taiwan’s Food and Drug Administration (TFDA). Notably, Taiwan has also authorized Hunterase ICV, an intracerebroventricular infusion alternative named Irifaze ICV in the region. With these latest approvals, Hunterase IV can now be marketed in 14 countries, while its ICV counterpart is available in four countries.
Hunter syndrome, a rare genetic disorder primarily affecting males, arises from a deficiency in lysosomal enzymes that are essential for breaking down glycosaminoglycans (GAGs). This lack leads to severe physical and cognitive challenges, including skeletal abnormalities and heart issues, which greatly impair quality of life. The incidence of this syndrome is estimated to occur in about 1 in 100,000 to 150,000 live male births worldwide. As GC Biopharma noted, both formulations of Hunterase are designed to fill an urgent gap in treatment options, particularly in regions where patient access to existing therapies is limited.
India presents a significant opportunity for growth in the rare disease market. The approval for the intravenous formulation of Hunterase IV is especially critical given the current inadequate patient treatment rate in the country. This is complemented by Taiwan’s dual approval system, which provides a robust framework for early screening and patient support in addressing Hunter syndrome.
Eun-Chul Huh, CEO of GC Biopharma, expressed his thoughts on these approvals, emphasizing their importance in catering to the unmet medical needs of Asian patients who previously faced a lack of effective treatments. He stated, "These approvals are significant as they address the unmet medical needs of local Asian patients who previously lacked sufficient treatment options. We will continue to dedicate our efforts to improving the quality of life for patients worldwide."
One of the innovative aspects of Hunterase ICV is its delivery method, which involves directly infusing the therapeutic enzyme into the cerebral ventricles, thereby bypassing the blood-brain barrier (BBB) to provide targeted help for cognitive impairments stemming from the disease. Notably, severe Hunter syndrome cases affect roughly 70% of the patient population, representing a pressing need for effective symtomatic treatment strategies for cognitive health.
GC Biopharma has a heritage of over 50 years in developing and manufacturing plasma-derived products and vaccines, with a commitment to addressing the needs of patients with rare diseases among its core missions. The firm's continuous innovation and expansion into the global markets illustrate its focus on not only sustaining its footprint in the industry but also meeting the growing demands of future healthcare needs. With the recent approvals in India and Taiwan, the company sets the stage for further enhancing its capabilities and presence in Asian markets, particularly in addressing rare diseases and related therapeutic innovations.
The successful entry of Hunterase IV and Hunterase ICV into India and Taiwan demonstrates GC Biopharma’s strategic approach to penetrate the Asian healthcare sector, ensuring that patients with rare diseases receive the urgent care they need. For more information about GC Biopharma and their commitment to healthcare innovation, visit GC Biopharma's website.
On August 24, 2026, GC Biopharma announced that its Hunter syndrome therapy, Hunterase IV, has received the go-ahead from India’s Central Drugs Standard Control Organisation (CDSCO) as well as Taiwan’s Food and Drug Administration (TFDA). Notably, Taiwan has also authorized Hunterase ICV, an intracerebroventricular infusion alternative named Irifaze ICV in the region. With these latest approvals, Hunterase IV can now be marketed in 14 countries, while its ICV counterpart is available in four countries.
Hunter syndrome, a rare genetic disorder primarily affecting males, arises from a deficiency in lysosomal enzymes that are essential for breaking down glycosaminoglycans (GAGs). This lack leads to severe physical and cognitive challenges, including skeletal abnormalities and heart issues, which greatly impair quality of life. The incidence of this syndrome is estimated to occur in about 1 in 100,000 to 150,000 live male births worldwide. As GC Biopharma noted, both formulations of Hunterase are designed to fill an urgent gap in treatment options, particularly in regions where patient access to existing therapies is limited.
India presents a significant opportunity for growth in the rare disease market. The approval for the intravenous formulation of Hunterase IV is especially critical given the current inadequate patient treatment rate in the country. This is complemented by Taiwan’s dual approval system, which provides a robust framework for early screening and patient support in addressing Hunter syndrome.
Eun-Chul Huh, CEO of GC Biopharma, expressed his thoughts on these approvals, emphasizing their importance in catering to the unmet medical needs of Asian patients who previously faced a lack of effective treatments. He stated, "These approvals are significant as they address the unmet medical needs of local Asian patients who previously lacked sufficient treatment options. We will continue to dedicate our efforts to improving the quality of life for patients worldwide."
One of the innovative aspects of Hunterase ICV is its delivery method, which involves directly infusing the therapeutic enzyme into the cerebral ventricles, thereby bypassing the blood-brain barrier (BBB) to provide targeted help for cognitive impairments stemming from the disease. Notably, severe Hunter syndrome cases affect roughly 70% of the patient population, representing a pressing need for effective symtomatic treatment strategies for cognitive health.
GC Biopharma has a heritage of over 50 years in developing and manufacturing plasma-derived products and vaccines, with a commitment to addressing the needs of patients with rare diseases among its core missions. The firm's continuous innovation and expansion into the global markets illustrate its focus on not only sustaining its footprint in the industry but also meeting the growing demands of future healthcare needs. With the recent approvals in India and Taiwan, the company sets the stage for further enhancing its capabilities and presence in Asian markets, particularly in addressing rare diseases and related therapeutic innovations.
The successful entry of Hunterase IV and Hunterase ICV into India and Taiwan demonstrates GC Biopharma’s strategic approach to penetrate the Asian healthcare sector, ensuring that patients with rare diseases receive the urgent care they need. For more information about GC Biopharma and their commitment to healthcare innovation, visit GC Biopharma's website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.